Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models
Science Translational Medicine · 06.08.2025 · 17 (810)
DOI: 10.1126/scitranslmed.adn5400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 06.08.2025. Verfasst von Xinyue Zhou und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Receptors, Aryl Hydrocarbon, Neoplastic Stem Cells, Leukemia, Myeloid, Acute, Transcription Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Developing strategies to enhance the response to bromodomain and extraterminal domain (BET) inhibitors and effectively eradicate cancer stem cells would represent a major cancer treatment advance against leukemia. Through a functional CRISPR screen, we identified the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, as a critical regulator of MYC expression and BET inhibitor sensitivity in human acute myeloid leukemia (AML). Constitutive or pharmacological activation of AHR repressed MYC and synergized with BET inhibitors to inhibit MYC transcription and suppress leukemia growth across diverse AML models. Mechanistically, AHR directly up-regulated a noncanonical target, ELMSAN1, a component of the MiDAC histone deacetylase complex, which promotes histone deacetylation at MYC regulatory elements. ELMSAN1 depletion led to up-regulation of MYC and impaired AHR signaling–induced BET inhibitor sensitization. In vivo, AHR agonists enhanced BET inhibitor efficacy in patient-derived xenografts and murine leukemia models, enabling the use of lower BET inhibitor doses while preserving therapeutic benefit and reducing toxicity. This combination suppressed leukemia stem cell (LSC) gene signatures and reduced LSC frequency, with minimal impact on normal hematopoietic stem and progenitor cells in both human cord blood xenografts and immunocompetent mouse models. Together, these findings uncover a MYC-repressive, nongenetic AHR-ELMSAN1 axis that enhances BET-targeting therapies and selectively impairs LSCs, providing a compelling rationale for clinical translation in AML and potentially other MYC-driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
- Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A1, Canada.
ORCID-Profile: Xinyue Zhou, Steven Moreira, Cecilia Restelli, Hong Wang, Emily Tsao, Pengcheng Zhang, Harish Kumar, Zaldy Balde, Ana Vujovic, Lina Liu, Nicholas Wong, Andrea Arruda, Mark D Minden, Yang Zhou, Jun Qi, Chunliang Li, Kristin J Hope, Rui Lu
Förderung
- NCI NIH HHS
Zitieren
APA
Zhou, X., Moreira, S., Restelli, C., Wang, H., Jahangiri, S., Aryal, S., Tsao, E., Zhang, P., Niu, M., Kumar, H., Balde, Z., Vujovic, A., Liu, L., Wong, N., Arruda, A., Minden, M. D., Zhou, Y., Ravi, B., Qi, J., …, & Lu, R. (2025). Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Science Translational Medicine, 17(810). https://doi.org/10.1126/scitranslmed.adn5400
Vancouver
Zhou X, Moreira S, Restelli C, Wang H, Jahangiri S, Aryal S, et al. Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models. Science Translational Medicine. 2025;17(810). doi:10.1126/scitranslmed.adn5400
BibTeX
@article{Zhou2025,
author = {Zhou, Xinyue and Moreira, Steven and Restelli, Cecilia and Wang, Hong and Jahangiri, Soheil and Aryal, Sajesan and Tsao, Emily and Zhang, Pengcheng and Niu, Mingming and Kumar, Harish and Balde, Zaldy and Vujovic, Ana and Liu, Lina and Wong, Nicholas and Arruda, Andrea and Minden, Mark D and Zhou, Yang and Ravi, Bhatia and Qi, Jun and Li, Chunliang and Hope, Kristin J and Lu, Rui},
title = {Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {810},
doi = {10.1126/scitranslmed.adn5400}
}
EUVIMED